Tag: HCPCS Level II Codes for COVID-19 Antibody Therapy

Two New Codes for COVID-19 Antibody Therapy

A new investigational monoclonal antibody therapy for Medicare patients with mild to moderate COVID-19 warrants new codes. The Centers for Medicare & Medicaid Services (CMS) announced Dec. 3 that it is implementing two new HCPCS Level II codes for Regeneron’s antibody casirivimab and imdevimab (REGN-COV2), effective for dates of service on or after Nov. 21. How To […]
Learn More

Request a Free Quote

    Enter the Captcha: captcha